Fig. 1From: Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory studySerum biomarkers were measured at baseline, after each 2 cycles of chemotherapy, and at 3-month, 6-month, and 12-month follow-up (empty arrows)Back to article page